文献速递衰弱、肌少症与跌倒多重用药

苯二氮䓬类使用是否影响生活方式干预效果:SPRINTT试验二次分析

Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial.
PubMed 文献 · Age Ageing · 2026-01-01

本研究为SPRINTT试验二次分析,纳入1506名衰弱老年人,评估苯二氮䓬使用是否削弱生活方式干预(运动+营养咨询)对移动残疾的预防效果。

要点

  • 在SPPB 3-7的衰弱老年人中,多组分干预仅对非苯二氮䓬使用者降低移动残疾风险。
  • 纵向暴露分析结果类似,SPPB 3-7亚组非使用者HR=0.79,使用者HR=1.13。

核心结论

  • 在衰弱老年人中,苯二氮䓬使用显著削弱生活方式干预预防移动残疾的效果。

研究设计与样本

  • SPRINTT试验的二次分析,纳入1506名参与者(平均年龄78.9岁,71.5%女性,干预组753例vs对照组753例)。

主要发现

  • 总体分析中,基线苯二氮䓬使用下,多组分干预对非使用者HR=0.86(95%CI 0.72-1.03),对使用者HR=1.04(95%CI 0.67-1.62)。

临床怎么用

  • 对衰弱老年人应考虑谨慎使用苯二氮䓬类药物,以避免削弱生活方式干预的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Benzodiazepine use is prevalent among older adults despite its recognised negative effects, including increased risk of falls, fractures and decline in functional status. Lifestyle interventions can preserve physical function and reduce the risk of disability. This study investigates whether benzodiazepine use reduces the effectiveness of lifestyle-based interventions on mobility disability. METHODS: We performed a secondary analysis of the 'Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies' trial. The lifestyle intervention consisted of physical exercise and nutritional counselling. Benzodiazepine use was assessed based on baseline or longitudinal exposure (defined as use at baseline plus use at two or more additional time points). Cox regression models were used to ascertain the association between benzodiazepine use and mobility disability incidence. A separate analysis was conducted among participants with a Short Physical Performance Battery (SPPB) score 3 to 7. RESULTS: Among the 1506 participants included (mean age 78.9 years; 71.5% female; 753 intervention vs. 753 control), 211 (14.0%) reported benzodiazepine use at baseline. Overall, 55.0% of baseline benzodiazepine users and 43.6% of non-users developed mobility disability during the follow-up (P = .003). When baseline benzodiazepine use was considered, no significant effect associated with multicomponent intervention (MCI) was shown among non-users (Hazard Ratio (HR) = 0.86; 95% Confidence Interval (CI) 0.72-1.03) and users (HR = 1.04; CI 0.67-1.62). In the subgroup of participants with SPPB scores 3 to 7, a significant effect of the MCI was observed only among non-users (HR = 0.80, 95% CI 0.66-0.97), while no 'association' was detected among users (HR = 1.06; 95% CI 0.65-1.71, P for interaction = .035). When longitudinal benzodiazepine exposure was considered, similar results were observed. In particular, in the SPPB score 3 to 7 subgroup, the beneficial effect of the MCI was observed only among non-users (HR = 0.79; 95% CI 0.64-0.96), while no 'association' was detected among users (HR = 1.13; 95% CI 0.60-2.13, P for interaction = .035). CONCLUSION: In frail older adults, benzodiazepine use significantly blunts the effectiveness of lifestyle interventions for preventing mobility disability. These findings support a prudent approach to benzodiazepine use in frail older patients.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Levati E, Zazzara MB, Giuli D, et al. Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial. Age Ageing. 2026. PMID: 42685256. doi:10.1093/ageing/afag257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。